FDA Approves New High-Capacity Insulin Pen

The FDA has approved Toujeo (insulin glargine 300 Units/mL) Max SoloStar, a long-acting insulin pen, which holds 900 Units of Toujeo and provides up to 160 Units/mL in a single injection.

Due to its capacity, the Max SoloStar could help to reduce the number of pens adults are prescribed, allowing for fewer refills.
____________________________________________________________________________________

RELATED CONTENT
FDA Approves Updated Tresiba Label
FDA Approves New Diabetic Macular Edema Treatment Option
____________________________________________________________________________________

Toujeo was originally approved by the FDA in February 2015 to improve glycemic control in adults living with type 1 and type 2 diabetes.

Potential side effects include swelling, weight gain, low potassium, and injection site reactions.

—Michael Potts

Reference:

FDA approves Toujeo® Max SoloStar® [press release]. March 27, 2018. http://www.news.sanofi.us/2018-03-27-FDA-approves-Toujeo-R-Max-SoloStar-R.